Core Viewpoint - Beijing Health (02389.HK) announced the resignation of its executive director, Xiao Jianwei, effective from October 10, 2025, due to regulatory actions by the Stock Exchange [1] Group 1 - The resignation of Xiao Jianwei is a direct response to regulatory actions taken by the Stock Exchange [1] - The effective date of the resignation is set for October 10, 2025 [1]

Core Viewpoint - Beijing Health (02389) announced the resignation of Mr. Xiao Jianwei as the executive director of the company, effective from October 10, 2025, due to regulatory actions by the Stock Exchange [1] Group 1 - The resignation is a result of regulatory actions and related outcomes concerning Mr. Xiao Jianwei [1]

為 免 生 疑 問，監 管 通 訊 僅 與 東 方 滙 財 有 關，且（除 上 文 有 關 蕭 先 生 外）並 不 涉 及 本 公 司 任 何 董 事 或 高 級 管 理 層。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （股份代號： ） （於開曼群島註冊成立的有限公司） 2389 (1)有關遵守上市規則第13.51B(2)及13.51(2)(h)條之公告 及 (2)執行董事辭任 有關遵守上市規則第13.51B(2)及13.51(2)(h)條之公告 本 公 告 由 北 京 健 康（控 股）有 限 公 司（「本公司」，連 同 其 附 屬 公 司 為「本集團」）根 據 香 港 聯 合 交 易 所 有 限 公 司（「聯交所」）證 券 上 市 規 則（「上市規則」）第13.51B(2) 條及第13.51(2)(h)條 而 作 出。 茲 提 述 聯 交 所 於 二 零 二 五 年 十 月 八 日 刊 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京健康(控股)有限公司 呈交日期: 2025年9月30日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02389 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.2 HKD | | | 2,000,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.2 HKD | | | 2,000,000,000 | 本 ...

Financial Performance - Revenue for the six months ended June 30, 2025, increased to HK$76,587,000, up 4.2% from HK$73,307,000 in 2024[5] - Gross profit rose to HK$20,395,000, representing a 24.5% increase compared to HK$16,382,000 in the previous year[5] - Other income and gains significantly improved to HK$26,133,000 from a loss of HK$10,922,000 in 2024[5] - Loss before tax decreased to HK$30,312,000, down 49.8% from HK$60,342,000 in the same period last year[5] - Loss for the period was HK$29,312,000, a reduction of 49.1% compared to HK$57,579,000 in 2024[6] - Total comprehensive loss for the period was HK$23,016,000, down from HK$69,439,000 in the previous year[6] - Basic and diluted loss per share attributable to ordinary equity holders of the parent was HK(0.48) cents, improved from HK(0.93) cents in 2024[7] Assets and Liabilities - Total non-current assets decreased from HK$1,398,050,000 as of December 31, 2024, to HK$1,342,849,000 as of June 30, 2025, representing a decline of approximately 4.0%[8] - Current assets increased from HK$552,116,000 as of December 31, 2024, to HK$576,273,000 as of June 30, 2025, reflecting an increase of about 4.4%[8] - Net current assets improved from HK$414,105,000 as of December 31, 2024, to HK$448,646,000 as of June 30, 2025, indicating a growth of approximately 8.3%[8] - Total current liabilities decreased from HK$138,011,000 as of December 31, 2024, to HK$127,627,000 as of June 30, 2025, a reduction of about 7.5%[8] - Total non-current liabilities remained relatively stable, with a slight increase from HK$71,729,000 as of December 31, 2024, to HK$71,807,000 as of June 30, 2025[9] - Net assets decreased from HK$1,740,426,000 as of December 31, 2024, to HK$1,719,688,000 as of June 30, 2025, a decline of approximately 1.2%[9] Cash Flow and Investments - Net cash flows generated from operating activities amounted to HK$12,556,000, a significant improvement from a cash outflow of HK$36,938,000 in the same period of 2024[14] - Cash flows from investing activities generated HK$24,865,000, compared to a cash outflow of HK$11,995,000 in 2024, indicating a positive shift in investment performance[15] - The company reported a net increase in cash and cash equivalents of HK$38,161,000, contrasting with a decrease of HK$51,711,000 in the previous year[17] - Cash and cash equivalents at the end of the period stood at HK$117,168,000, up from HK$100,998,000 in 2024[17] Revenue Sources - For the six months ended June 30, 2025, the Group's revenue from contracts with customers was approximately HK$76,587,000, an increase of 4% from HK$73,307,000 for the same period in 2024[31] - Revenue from the sale of goods was HK$69,608,000, up from HK$68,078,000, while revenue from rendering services increased to HK$6,979,000 from HK$5,229,000[32] - 100% of the Group's revenue during the period was generated from customers in Mainland China, with over 92% of non-current assets located in the same region[27] Geriatric Care Business - As of June 30, 2025, the Group operated six geriatric care institutions with a total of 1,243 beds, including 955 beds for medical care services, achieving an average occupancy rate of over 70%[177] - Revenue from geriatric care institutions reached RMB 26.42 million in the first half of 2025, representing a year-on-year increase of 22% compared to RMB 21.64 million in the first half of 2024[177] - The average occupancy rate of the Group's geriatric care institutions was 73% in the first half of 2025, compared to 56% in the first half of 2024[180] - The Group's nursing institutions maintained full occupancy throughout the year, indicating strong recognition from customers and government[176] Share Options and Capital - The company has a share capital of HK$1,211,754,000 as of June 30, 2025, unchanged from December 31, 2024[100] - The 2013 share option scheme has expired as of May 23, 2023, with 146,500,000 share options lapsed and HK$51,934,000 transferred to accumulated losses during the period[101] - The total number of share options granted to directors and substantial shareholders amounts to 60,000,000, with 20,000,000 lapsing during the period[112] - The total number of share options exercised during the period was zero, indicating a potential lack of liquidity or market confidence[111] Financial Assets and Liabilities - The fair value of financial assets measured at fair value as of June 30, 2025, totals HK$165,886,000, with HK$47,209,000 classified as Level 1 and HK$113,675,000 as Level 2[140] - The Group's total financial assets at fair value through profit or loss amount to HK$141,641,000 as of June 30, 2025[140] - The total fair value of financial assets at fair value through profit or loss included HK$118,441,000 in bank wealth management products classified as Level 2[144] Management and Governance - Compensation for key management personnel for the six months ended June 30, 2025, totaled HK$4,513,000, an increase from HK$2,267,000 in the same period of 2024[130] - Performance-related bonuses for key management personnel for the six months ended June 30, 2025, were HK$2,100,000, compared to none in the same period of 2024[130] Contingent Liabilities and Commitments - As of June 30, 2025, the Group had no significant contingent liabilities[123] - The Group's capital commitments as of June 30, 2025, include contracted but not provided for amounts of HK$15,156,000, down from HK$75,822,000 as of December 31, 2024[127]

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號：2389) NOTIFICATION LETTER 通 知 信 函 Dear Non-registered Shareholder (Note 1) , 22 September 2025 • Interim Report 2025 Please provide your email address to the Company via Hong Kong Securities Clearing Company Limited ("HKSCC") if you would like to receive an email notification of the publication of the Corporate Communication(s) (Note 2) on the Websites instead of receiving printed notification letter in future. If ...

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號：2389) NOTIFICATION LETTER 通知信函 Dear Shareholder(s), 22 September 2025 The following document(s) of Beijing Health (Holdings) Limited (the "Company") has/have been prepared in English and Chinese and is/are available on the websites of the Company at www.bjhl.com.hk and The Stock Exchange of Hong Kong Limited at www.hkexnews.hk (collectively the "Websites"):- • Interim Report 2025 If you have not provided us with an ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京健康(控股)有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02389 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.2 | HKD | | 2,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.2 | HKD | | 2,000,000,000 | 本月 ...

Group 1 - The core viewpoint of the article is that Beijing Health (02389.HK) reported its interim results for the first half of 2025, showing a modest revenue increase and a significant reduction in losses [1] Group 2 - The company's revenue for the first half of 2025 was HKD 76.587 million, representing a year-on-year growth of 4.47% [1] - The loss attributable to shareholders during the period was HKD 29.236 million, which is a 48.17% decrease compared to the previous year [1] - The basic loss per share was HKD 0.48 [1]

Core Viewpoint - Beijing Health (02389) reported a revenue of HKD 76.587 million for the six months ending June 30, 2025, representing a year-on-year increase of 4.47%. The loss attributable to equity holders of the parent company was HKD 29.236 million, a decrease of 48.17% compared to the previous year, with a basic loss per share of HKD 0.048 [1] Revenue Breakdown - The increase in revenue was primarily driven by the sales of healthcare products and the growth in elderly care business [1] - The healthcare products segment saw revenue growth due to the successful introduction of a new line of educational furniture, which has led to sustained sales increases that offset declines in hospital and elderly care furniture sales [1] - The elderly care business revenue increased mainly due to a rise in admission rates [1]